These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 1851231)

  • 1. In vitro effects of interleukin 1 on the synthesis of metalloproteases, TIMP, plasminogen activators and inhibitors in human articular cartilage.
    Martel-Pelletier J; Zafarullah M; Kodama S; Pelletier JP
    J Rheumatol Suppl; 1991 Feb; 27():80-4. PubMed ID: 1851231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Excess of metalloproteases over tissue inhibitor of metalloprotease may contribute to cartilage degradation in osteoarthritis and rheumatoid arthritis.
    Martel-Pelletier J; McCollum R; Fujimoto N; Obata K; Cloutier JM; Pelletier JP
    Lab Invest; 1994 Jun; 70(6):807-15. PubMed ID: 8015285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulation of plasminogen activation, matrix metalloproteinases and urokinase-type plasminogen activator-mediated extracellular matrix degradation in human osteosarcoma cell line MG63 by interleukin-1 alpha.
    de Bart AC; Quax PH; Löwik CW; Verheijen JH
    J Bone Miner Res; 1995 Sep; 10(9):1374-84. PubMed ID: 7502710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulation of mRNA levels for urinary- and tissue-type plasminogen activator and plasminogen activator inhibitors 1 and 2 in human fibroblasts by interleukin 1.
    Michel JB; Quertermous T
    J Immunol; 1989 Aug; 143(3):890-5. PubMed ID: 2501387
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Down-regulation of proteolytic activity in 12-O-tetradecanoyl-phorbol-13-acetate-induced K562 leukemia cell cultures: depletion of active urokinase by excess type 1 plasminogen activator inhibitor.
    Alitalo R; Andersson LC; Tapiovaara H; Sistonen L; Vaheri A; Stephens R
    J Cell Physiol; 1989 Jul; 140(1):119-30. PubMed ID: 2500450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of indomethacin on the production of matrix metalloproteinase-3 and tissue inhibitor of metalloproteinases-1 by human articular chondrocytes.
    Yamada H; Kikuchi T; Nemoto O; Obata K; Sato H; Seiki M; Shinmei M
    J Rheumatol; 1996 Oct; 23(10):1739-43. PubMed ID: 8895151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of IL-1alpha on the expression of matrix metalloproteinases, plasminogen activators, and their inhibitors in osteoblastic ROS 17/2.8 cells.
    Fujisaki K; Tanabe N; Suzuki N; Mitsui N; Oka H; Ito K; Maeno M
    Life Sci; 2006 Mar; 78(17):1975-82. PubMed ID: 16313928
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suppression of matrix metalloproteinase-3 synthesis by interleukin-4 in human articular chondrocytes.
    Nemoto O; Yamada H; Kikuchi T; Shinmei M; Obata K; Sato H; Seiki M
    J Rheumatol; 1997 Sep; 24(9):1774-9. PubMed ID: 9292803
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulation of tissue plasminogen activator and plasminogen activator inhibitor-1 by transforming growth factor-beta in human retinal glial cells.
    Schacke W; Beck KF; Pfeilschifter J; Koch F; Hattenbach LO
    Invest Ophthalmol Vis Sci; 2002 Aug; 43(8):2799-805. PubMed ID: 12147618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulation of urokinase-type plasminogen activator and plasminogen activator inhibitor-2 expression by U-937 mononuclear phagocytes. Effects of 1 alpha, 25-dihydroxyvitamin D3 and phorbol ester.
    Gyetko MR; Webb AC; Sitrin RG
    J Immunol; 1988 Oct; 141(8):2693-8. PubMed ID: 3139763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulation of the catabolic effects of interleukin-1 beta on human articular chondrocytes by transforming growth factor-beta.
    Lum ZP; Hakala BE; Mort JS; Recklies AD
    J Cell Physiol; 1996 Feb; 166(2):351-9. PubMed ID: 8591995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of tissue-type plasminogen activator and its inhibitor couples with development of capillary network by human microvascular endothelial cells on Matrigel.
    Ito K; Ryuto M; Ushiro S; Ono M; Sugenoya A; Kuraoka A; Shibata Y; Kuwano M
    J Cell Physiol; 1995 Feb; 162(2):213-24. PubMed ID: 7822431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Uncoordinate regulation of collagenase, stromelysin, and tissue inhibitor of metalloproteinases genes by prostaglandin E2: selective enhancement of collagenase gene expression in human dermal fibroblasts in culture.
    Mauviel A; Halcin C; Vasiloudes P; Parks WC; Kurkinen M; Uitto J
    J Cell Biochem; 1994 Apr; 54(4):465-72. PubMed ID: 8014195
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucocorticoid modulation of plasminogen activators and of one of their inhibitors in the human mammary carcinoma cell line MDA-MB-231.
    Busso N; Belin D; Failly-Crépin C; Vassalli JD
    Cancer Res; 1987 Jan; 47(2):364-70. PubMed ID: 3098408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protein and messenger RNA levels of plasminogen activators and inhibitors analyzed in 22 human tumor cell lines.
    Quax PH; van Leeuwen RT; Verspaget HW; Verheijen JH
    Cancer Res; 1990 Mar; 50(5):1488-94. PubMed ID: 2105839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cartilage synthesizes the serine protease inhibitor PAI-1: support for the involvement of serine proteases in cartilage remodeling.
    Treadwell BV; Pavia M; Towle CA; Cooley VJ; Mankin HJ
    J Orthop Res; 1991 May; 9(3):309-16. PubMed ID: 1901356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interaction between plasminogen activator inhibitor type 1 (PAI-1) bound to fibrin and either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA). Binding of t-PA/PAI-1 complexes to fibrin mediated by both the finger and the kringle-2 domain of t-PA.
    Wagner OF; de Vries C; Hohmann C; Veerman H; Pannekoek H
    J Clin Invest; 1989 Aug; 84(2):647-55. PubMed ID: 2503541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation of plasminogen activator activity in arthritic joints.
    Hamilton JA; Hart PH; Leizer T; Vitti GF; Campbell IK
    J Rheumatol Suppl; 1991 Feb; 27():106-9. PubMed ID: 1902874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imbalance between the mechanisms of activation and inhibition of metalloproteases in the early lesions of experimental osteoarthritis.
    Pelletier JP; Mineau F; Faure MP; Martel-Pelletier J
    Arthritis Rheum; 1990 Oct; 33(10):1466-76. PubMed ID: 2171538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasmin, plasminogen activators and inhibitor in human osteoarthritic cartilage.
    Martel-Pelletier J; Faure MP; McCollum R; Mineau F; Cloutier JM; Pelletier JP
    J Rheumatol; 1991 Dec; 18(12):1863-71. PubMed ID: 1724464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.